Novira Therapeutics

Novira is an antiviral drug discovery company launched in 2009 that is focused on the discovery of novel, first-in-class therapeutics for the treatment of HBV and HIV, two global diseases in need of better therapies. The company is led by seasoned pharmaceutical industry executives with proven records of success in drug discovery. The company has identified and is further optimizing a promising pipeline of drugs that disrupt virus capsid assembly of HIV and HBV using an efficient and innovative model of biomedical research.

Proprietary Technology

Novira's HBV and HIV antiviral drugs bind to and disrupt the function of a virus protein called "capsid" or "core". Viral capsids represent an exciting new class of antiviral targets with decisive pharmacological and genetic validation. Our HBV and HIV capsid inhibitors are ideally suited for development of novel cross-class combination regimens that will deliver superior benefits for the treatment and prevention of viral infections. HBV is the company’s lead program and Novira expects to complete animal proof of concept/efficacy studies within the next 6-9 months, initiate preclinical development in 2012, and enter human safety and efficacy studies in 2013.new